Centre Hospitalier Prive Saint-Gregoire — Clinical Trial Site

46 Registered trials

20 Currently recruiting

Organisation

Centre Hospitalier Prive Saint-Gregoire

Location

Saint-Gregoire, France

Identifier

ORG-100043517

Address

6 Boulevard De La Boutiere, Cs 56816, 35760, France

Departments

Cancerologie
Centre oncologie Saint Vincent - Oncologie et radiothérapie
Chirurgie digestive
Département de radiothérapie
Départment D'Oncologie Médicale
Medical Oncology
NA
Nord CHP
ONCO RADIOTHERAPY
ONCOLOGIE
Oncologie médicale
Oncologie Radiothérapie
Oncologie/ Radiothérapie
Oncology
Oncology Radiotherapie
Oncology-Radiotherapy
Radiotherapy
Service d'Oncologie
Service Oncologie
Urology

Clinical trials at this site (46)

Search interface

Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris… Ended

2023-508827-10-00 Patients with primary operable stage II, grade 2 or 3, 4 2025-10-13
A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Ended

2024-517422-25-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-05-22
A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab… Ended

2024-511650-50-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-01-17
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
DARIUS : A randomized non-comparative phase II multicentric trial on short term DARolutamide (ODM-201) concomitant to radiation therapy for … Ended

2023-509494-23-00 Adult patients with intermediate unfavorable risk prost 4 2023-02-20
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended

2024-514480-26-00 Post-menopausal women with localized luminal A breast c 4 2022-10-12
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc… Ended

2023-510097-14-00 Patients with MMR deficient relapse or advanced / metas 5 2022-04-15
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended

2024-510809-28-00 Metastatic Castration-sensitive Prostate Cancer 5 2021-09-27
Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castratio… Ended

2024-516481-11-00 Metastatic Castration-Resistant Prostate Cancer 5 2020-09-22
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 resected squamous cell carcinoma of head and neck 5 2018-08-10
Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Squamous cell carcinoma, previously untreated Stage III 5 2017-09-14
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended

2024-517489-41-00 High-risk stage III colon cancer 5 2017-03-27
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in… Ended

2024-513521-23-00 Prostate Cancer 5 2015-08-19
A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient… Ended

2024-517622-25-00 Patients with localized prostate cancer and high-risk f 5 2013-12-06
Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco… Ended

2024-516996-34-00 oestrogen-receptor (ER)-positive HER2-negative breast c 5 2012-04-12
A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer Ended

2022-502982-49-00 Metastatic Castration-Resistant Prostate Cancer 4 2024-07-15
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Metastatic Breast Cancer HR+, HER2- 4 2023-10-19
A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended

2022-501078-20-00 Metastatic Castration-resistant Prostate Cancer 4 2023-05-15
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended

2023-508528-36-00 Resected squamous cell carcinoma of the head and neck 5 2022-12-16
The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic… Ended

2024-517251-12-00 Recurrent or metastatic head and neck squamous cell car 5 2021-11-02
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc… Ended

2023-503807-27-00 Biliary tract carcinoma 4